Trial ID 18263 | Maryland Oncology Hematology Trial ID 18263 – Maryland Oncology Hematology

Trial ID 18263

Trial Information - Phase II

A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib 

Protocol ID: BGB-3111-215

Sponsor: BeiGene USA Inc.

Status: STAR Trial

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Lymphoma

Status

STAR Trial

Sponsor

BeiGene USA Inc.

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology